Beam Therapeutics (BEAM) Insider Sale: 467 Shares at $24.53

Beam Therapeutics insider Bethany J. Cavanagh, who serves as SVP, Finance and Treasurer, reported a non‑discretionary sale of 467 shares of common stock on 10/01/2025 at a price of $24.53 per share.

Rhea-AI Filing Summary

Beam Therapeutics insider Bethany J. Cavanagh, who serves as SVP, Finance and Treasurer, reported a non‑discretionary sale of 467 shares of common stock on 10/01/2025 at a price of $24.53 per share. The filing shows 44,045 shares remained beneficially owned by the reporting person after the transaction. The form states the shares were sold automatically to cover tax withholding obligations arising from the vesting of restricted stock units granted on 9/30/2021 and 9/30/2024, and the sales were effected under a Rule 10b5‑1 trading plan adopted on 8/9/2024. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025.

Positive

• Sale was automatic under a Rule 10b5‑1 plan dated 8/9/2024, indicating planned, non‑discretionary trading
• Transaction explicitly covered tax withholding for RSU vesting on 9/30/2021 and 9/30/2024, clarifying the purpose of the sale
• Filing reports remaining beneficial ownership of 44,045 shares, providing transparency on insider holdings

Negative

• Disposition of 467 shares reduced the insider's stake, as reported
• Sale price of $24.53 realized on 10/01/2025, a concrete monetization event by an officer

Insights

Corporate Governance Analyst

TL;DR: Routine tax‑cover sale under a 10b5‑1 plan; no new grants or discretionary selling disclosed.

The report documents an automatic sale of 467 shares at $24.53 to satisfy tax withholding following RSU vesting on 9/30/2021 and 9/30/2024. The filing explicitly attributes the transaction to a pre‑existing Rule 10b5‑1 plan adopted on 8/9/2024, which indicates the sale was planned rather than discretionary.

This is a standard compliance disclosure under Section 16; the filing also records remaining beneficial ownership of 44,045 shares. No other derivative transactions, new grants, or departures are disclosed in this Form 4.

Insider Trade Summary

Net Seller: 467 shares

Net Sell 1 txn

Insider Cavanagh Bethany J

Role SVP, Finance and Treasurer

Sold 467 shs ($11K)

Type	Security	Shares	Price	Value
Sale	Common Stock	467	$24.53	$11K

Holdings After Transaction: Common Stock — 44,045 shares (Direct)

Footnotes (1)

1. F1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2021 and September 30, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Beam Therapeutics insider Bethany Cavanagh report on Form 4 (BEAM)?

The Form 4 reports an automatic sale of 467 common shares at $24.53 per share on 10/01/2025, leaving 44,045 shares beneficially owned.

Why were the shares sold according to the Form 4 for BEAM?

The filing states the shares were sold to cover tax withholding obligations arising from RSU vesting on 9/30/2021 and 9/30/2024.

Was the sale by the BEAM reporting person discretionary?

No. The sale was effected pursuant to a pre‑existing Rule 10b5‑1 trading plan adopted on 8/9/2024, and described as non‑discretionary.

How many shares did the reporting person own after the transaction?

The Form 4 shows the reporting person beneficially owned 44,045 shares following the reported sale.

Who signed the Form 4 for the filing?

The Form 4 was signed by an attorney‑in‑fact, Christine Bellon, on behalf of the reporting person on 10/03/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Cavanagh Bethany J

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance and Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		S(1)		467	D	$24.53	44,045	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2021 and September 30, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024.

	By: /s/ Christine Bellon, Attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.